Effect of Alendronate Sodium on Osteoporosis after Spinal cord Injury
Alendronate, as a potential bisphosphonate, has been widely used in the treatment of osteoporosis after spinal cord injury. Alendronate can improve bone mineral density, inhibit bone turnover rate and reduce the incidence of fracture. Alendronate can bind to hydroxyapatite in bone with high affinity, and has a certain degree of affinity to osteoclast. In this paper, the effects of alendronate sodium (AlN) on bone mineral density and biomechanical properties of femur in SCI rats were studied. 8 weeks after the operation, the femur was taken for bone mineral density and biomechanical test. Results the bone mineral density and biomechanical parameters of femur in 8 weeks after spinal cord transection were significantly changed compared with sham group; compared with SCI group, the bone mineral density of femur in SCI + AlN group was significantly increased (P < 0.01); the elastic load value and the maximum load value were significantly increased (P < 0.01), and the maximum stress value was increased (P < 0.05). Conclusion 8 weeks after spinal cord transection, AlN can be used in the study of osteoporosis after SCI. Early application of AlN can reduce the loss of bone mass in the femur of SCI rats and improve the biomechanical properties of the femur of SCI rats.